Administration of Subcutaneous Teicoplanin in the Treatment of Osteoarticular Infections: Tolerance Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-03-31

Study Completion Date

2015-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a biomedical research, prospective, mono centric, tolerance study Of the administration of subcutaneous teicoplanin in the treatment of osteoarticular infections.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Teicoplanin-based Antimicrobial Therapy in Staphylococcus Aureus Bone and Joint Infection: Tolerance, Efficacy and Experience With Subcutaneous Administration

NCT03177369

Teicoplanin-based Antimicrobial Therapy Staphylococcus Aureus Bone and Joint Infection

COMPLETED

Impact of Pharmaceutical Interviews Regarding the Management of Adverse Effects Related to the Antibiotic Therapy Used to Treat Osteoarticular Infections During Return Home

NCT05248490

Bone and Joint Infection

COMPLETED NA

Study of Adverse Effects Occuring in Patients Receiving an Antibiotic Treatment With Temocillin

NCT03599999

Bacterial Infection With One or More Extended Spectrum Betalactamases Remaining Susceptible to Temocillin

COMPLETED

A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects

NCT02439359

Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)

COMPLETED PHASE1

Evaluation of the Efficacy and Safety of Suppressive Therapy With DALBAVANCINE in Device Infections

NCT06089044

Prosthesis-related Infections

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarticular Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

teicoplanin

this group receive the teicoplanin

Group Type EXPERIMENTAL

teicoplanin

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

teicoplanin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient over 18 years
* Inpatient orthopedic surgery
* Achieved a bone and joint infection documented gram + (staphylococci golden coagulase-negative staphylococci, enterococci, streptococci)
* Bacteria resistant to lincosamides, quinolones and rifampicin
* Bacteria susceptible to teicoplanin (MIC ≤ 4 mg / L)
* Balanced patient teicoplanin administered intravenously (2 successive doses between 30 and 40 mg / mL)

Exclusion Criteria

* Patient not affiliated to the social security
* Pregnant and lactating women
* Known hypersensitivity to teicoplanin (rash, ...)
* Patients with a central catheter or an implantable chamber
* Patient hemodialysis
* Patient has another participant biomedical research on a drug to prevent drug interactions
* Patient minor
* Patient major protected (protection of the court, wardship, trusteeship)
* Patient admitted for emergency or incapable of consent

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No